The Food and Drug Administration requires certified providers to dispense mifepristone, one of the drugs used in medication abortion, directly to the patient in a clinic, medical office, or hospital. This study’s findings indicate that removing that requirement could lead to more providers of medication abortion, including in regions with limited abortion access.
Researchers conducted a survey survey between August 2016 and March 2017 of a national sample of practicing OB-GYNs. They limited their sample to the 868 respondents who had reported having any abortion-seeking patients in the last year.
Currently, clinicians who want to provide medication abortions must stock the drug in their practice, adding up-front costs and administrative burdens. Removing this requirement could increase the number of medication abortion providers across the country, including in settings with limited access.
“The in-person dispensing requirement for mifepristone codified in the drug’s REMS is a barrier to clinician provision of the method. Removing this requirement could increase the number of medication abortion providers across the country, including in settings with limited access.”
The article, Obstetrician-gynecologist willingness to provide medication abortion with removal of the in-person dispensing requirement for mifepristone, is available in Contraception.